Table 3.
Differences in STI testing services by PrEP programme study design (N = 91)
| Programme indicators | Type of PrEP programme | p‐value | |||
|---|---|---|---|---|---|
| Routine implementation | Cohort Study | Demonstration project | RCT Study | ||
|
n (%) (N = 28) |
n (%) (N = 39) |
n (%) (N = 17) |
n (%) (N = 7) |
||
| Had STI testing before PrEP initiation | |||||
| Yes | 13 (46%) | 32 (82%) | 13 (77%) | 6 (86%) | 0.01 |
| Not stated | 15 (53%) | 7 (18%) | 4 (23%) | 1 (14%) | |
| Provided gonorrhoea testing | |||||
| Yes | 24 (86%) | 34 (87%) | 14 (82%) | 6 (86%) | 0.98 |
| Not stated | 4 (14%) | 5 (13%) | 3 (18%) | 1 (5%) | |
| Gonorrhoea testing frequency (N = 78) | |||||
| Every three months | 17 (71%) | 24 (71%) | 8 (57%) | 2 (33%) | 0.23 |
| Longer than three months interval | 5 (21%) | 9 (29%) | 5 (36%) | 4 (67%) | |
| Not stated | 2 (8%) | 1 (3%) | 1 (7%) | 0 (0%) | |
| Provided chlamydia testing | |||||
| Yes | 24 (86%) | 33 (85%) | 13 (77%) | 6 (86%) | 0.86 |
| Not stated | 4 (14%) | 6 (15%) | 4 (23%) | 1 (14%) | |
| Chlamydia testing frequency (N = 76) | |||||
| Every three months | 17 (71%) | 24 (73%) | 8 (57%) | 2 (33%) | 0.16 |
| Longer than every three months | 5 (21%) | 9 (27%) | 5 (43%) | 4 (67%) | |
| Not stated | 2 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Provided syphilis testing | |||||
| Yes | 24 (86%) | 32 (82%) | 13 (77%) | 7 (100%) | 0.54 |
| No stated | 4 (14%) | 7 (18%) | 4 (23%) | 0 (0%) | |
| Syphilis testing frequency (N = 76) | |||||
| Every three months | 16 (67%) | 26 (81%) | 9 (69%) | 2 (29%) | 0.02 |
| Longer than every three months | 5 (21%) | 6 (19%) | 4 (31%) | 5 (71%) | |
| Not stated | 3 (12%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Provided Hepatitis A testing | |||||
| Yes | 4 (14%) | 5 (13%) | 2 (11%) | 1 (14%) | 0.99 |
| Not stated | 24 (86%) | 34 (87%) | 15 (89%) | 6 (86%) | |
| Hepatitis A testing frequency (N = 12) | |||||
| Every three months | 1 (25%) | 4 (80%) | 1 (50%) | 0 (0%) | 0.28 |
| At baseline only | 3 (75%) | 1 (20%) | 1 (50%) | 1 (100%) | |
| Provided hepatitis A vaccination | |||||
| Yes | 4 (14%) | 1 (3%) | 2 (12%) | 1 (14%) | 0.33 |
| Not stated | 24 (86%) | 38 (97%) | 15 (88%) | 6 (86%) | |
| Provided Hepatitis B testing | |||||
| Yes | 14 (50%) | 18 (45%) | 15 (83%) | 2 (29%) | 0.01 |
| Not stated | 14 (50%) | 22 (55%) | 3 (17%) | 5 (71%) | |
| Hepatitis B testing frequency (N = 48) | |||||
| Testing at every 3/6/12 months | 3 (21%) | 7 (41%) | 10 (77%) | 1 (50%) | 0.31 |
| At baseline only | 8 (57%) | 6 (35%) | 3 (23%) | 1 (50%) | |
| Not stated | 3 (21%) | 4 (24%) | 2 (14%) | 0 (0%) | |
| Provided hepatitis B vaccination | |||||
| Yes | 5 (18%) | 5 (13%) | 6 (35%) | 1 (14%) | 0.25 |
| Not stated | 23 (82%) | 34 (87%) | 11 (65%) | 6 (86%) | |
| Provided hepatitis C testing | |||||
| Yes | 11 (39%) | 13 (33%) | 8 (47%) | 1 (14%) | 0.46 |
| Not stated | 17 (61%) | 26 (67%) | 9 (53%) | 6 (86%) | |
| Hepatitis C testing frequency (N = 33) | |||||
| Testing at every 3/6/12 months | 8 (73%) | 9 (69%) | 4 (50%) | 0 (0%) | 0.28 |
| At baseline only | 1 (9%) | 1 (8%) | 2 (25%) | 1 (100%) | |
| Not stated | 2 (18%) | 3 (23%) | 2 (25%) | 0 (0%) | |
| Provided HPV vaccination | |||||
| Yes | 3 (11%) | 0 (0%) | 2 (12%) | 0 (0%) | 0.14 |
| Not stated | 25 (89%) | 39 (100%) | 15 (88%) | 7 (100%) | |
| Numbers of STIs testedb (Range: 0 to 6) | |||||
| Mean (SD) | 3.36 (1.85) | 3.67(1.40) | 3.59 (1.73) | 3.29 (1.38) | 0.85 |
| Additional sexual health services provided | |||||
| Yes | 15 (54%) | 19 (49%) | 11 (65%) | 3 (43%) | 0.68 |
| Not stated | 13 (46%) | 20 (51%) | 6 (35%) | 4 (57%) | |
| Triple anatomical site STI screening availabled | |||||
| Yes | 14 (50%) | 15 (39%) | 5 (29%) | 5 (70%) | 0.21 |
| Not stated | 14 (50%) | 24 (61%) | 12 (71%) | 2 (30%) | |
| Provided antimicrobial resistance testing | |||||
| Yes | 1 (4%) | 4 (10%) | 1 (6%) | 1 (14%) | 0.67 |
| Not stated | 27 (96%) | 35 (90%) | 16 (94%) | 6 (86%) | |